We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
+12.81%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$225M
AUM Growth
-$5.82M
(-2.5%)
Cap. Flow
-$29.2M
Cap. Flow
% of AUM
-12.97%
Top 10 Holdings %
Top 10 Hldgs %
45.19%
Holding
92
New
27
Increased
21
Reduced
24
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sanofi
SNY
|
+$5.69M |
| 2 |
WMGI
Wright Medical Group Inc
WMGI
|
+$5.36M |
| 3 |
TVTY
Tivity Health, Inc. Common Stock
TVTY
|
+$5.15M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$4.63M |
| 5 |
RCM
R1 RCM Inc. Common Stock
RCM
|
+$4.26M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$11.9M |
| 2 |
Abbott
ABT
|
+$11.6M |
| 3 |
Johnson & Johnson
JNJ
|
+$7.46M |
| 4 |
Universal Health Services
UHS
|
+$7.16M |
| 5 |
AGN
Allergan plc
AGN
|
+$6.71M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.74% |
| 2 | Industrials | 2.11% |
| 3 | Financials | 2.08% |
| 4 | Technology | 0.89% |
| 5 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Fate Therapeutics
FATE
$286M
| $3.33M | 1.48% |
204,333
+121,761
| +147% | +$1.44M |
|
27
Iovance Biotherapeutics
IOVA
$1.82B
| $2.72M | 1.21% |
+242,169
| New | +$3.44M |
|
28
Boston Scientific
BSX
$69.5B
| $2.71M | 1.21% |
70,407
-2,434
| -3% | -$85K |
|
29
Icon
ICLR
$12.6B
| $2.48M | 1.1% |
+16,099
| New | +$2.31M |
|
30
Danaher
DHR
$137B
| $2.17M | 0.96% |
+22,502
| New | +$2.05M |
|
31
Quest Diagnostics
DGX
$25.7B
| $2.12M | 0.94% |
+19,673
| New | +$2.16M |
|
32
Ocular Therapeutix
OCUL
$1.79B
| $2.08M | 0.92% |
302,153
+159,378
| +112% | +$1M |
|
|
IIN
33
DELISTED
IntriCon Corporation
IIN
| $2M | 0.89% |
+35,494
| New | +$2.08M |
|
|
HRC
34
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $1.88M | 0.83% |
19,865
-23,012
| -54% | -$2.16M |
|
35
UnitedHealth
UNH
$376B
| $1.84M | 0.82% |
6,922
-9,945
| -59% | -$2.59M |
|
|
ARRY
36
DELISTED
Array Biopharma Inc
ARRY
| $1.71M | 0.76% |
112,700
+31,284
| +38% | +$479K |
|
|
NVRO
37
DELISTED
NEVRO CORP.
NVRO
| $1.38M | 0.61% |
24,171
+14,075
| +139% | +$880K |
|
38
Sarepta Therapeutics
SRPT
$1.57B
| $1.37M | 0.61% |
8,456
+1,742
| +26% | +$238K |
|
|
NXTM
39
DELISTED
NxStage Medical Inc.
NXTM
| $1.3M | 0.58% |
+46,513
| New | +$1.31M |
|
40
Viking Therapeutics
VKTX
$3.7B
| $1.25M | 0.56% |
71,977
+11,478
| +19% | +$137K |
|
41
Agilent Technologies
A
$39.1B
| $1.22M | 0.54% |
17,286
-12,125
| -41% | -$802K |
|
42
Puma Biotechnology
PBYI
$404M
| $1.15M | 0.51% |
25,081
-15,707
| -39% | -$757K |
|
|
MDRX
43
DELISTED
Veradigm Inc. Common Stock
MDRX
| $1.09M | 0.48% |
+76,494
| New | +$1.04M |
|
44
Axogen
AXGN
$2.27B
| $1.07M | 0.48% |
+29,074
| New | +$1.27M |
|
|
ADVM
45
DELISTED
Adverum Biotechnologies
ADVM
| $1.02M | 0.45% |
+16,884
| New | +$948K |
|
46
Pediatrix Medical
MD
$2.18B
| $978K | 0.44% |
20,959
+11,517
| +122% | +$529K |
|
47
Aldeyra Therapeutics
ALDX
$92.9M
| $966K | 0.43% |
+70,000
| New | +$568K |
|
|
SGMO
48
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $924K | 0.41% |
+54,523
| New | +$829K |
|
|
FOLD
49
DELISTED
Amicus Therapeutics
FOLD
| $856K | 0.38% |
70,768
+16,264
| +30% | +$227K |
|
50
MacroGenics
MGNX
$235M
| $846K | 0.38% |
+39,456
| New | +$841K |
|
Similar funds
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
HSCU
Endurant Capital Management's Q3 2018 Portfolio in Review
As of Q3 2018, Endurant Capital Management held 92 positions worth $225M, down 2.5% from $231M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Endurant Capital Management withdrew a net $29.2M in Q3 2018, closing 19 positions and reducing 24 holdings. Its most notable exit was Universal Health Services, an estimated $7.16M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Industrials and Financials.
Against the trend, Endurant Capital Management opened a new position in Sanofi worth $5.95M.
- Endurant Capital Management's largest Q3 2018 buy was Sanofi: 133,245 shares worth $5.95M.
- Endurant Capital Management added most to Wright Medical Group Inc in Q3 2018, an estimated $5.36M increase.
- Endurant Capital Management's biggest Q3 2018 reduction was Merck, cutting an estimated $11.9M.
- Endurant Capital Management fully exited Universal Health Services in Q3 2018, selling an estimated $7.16M.
- Endurant Capital Management's ten largest holdings make up 45% of its $225M portfolio in Q3 2018.
- Endurant Capital Management opened 27 new positions and closed 19 in Q3 2018.
- Endurant Capital Management's portfolio value fell 2.5% quarter-over-quarter to $225M.
Based on Endurant Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.